NCT02733679View on ClinicalTrials.gov

Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 29, 2016

Primary Completion Date

August 30, 2017

Study Completion Date

August 30, 2017

Conditions
Ataxia-Telangiectasia
Interventions
DRUG

Metformin

Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.

DRUG

Pioglitazone

Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.

Trial Locations (1)

DD19SY

Ninewells Hospital, Dundee

All Listed Sponsors
collaborator

University of Dundee

OTHER

lead

NHS Tayside

OTHER_GOV

NCT02733679 - Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone | Biotech Hunter | Biotech Hunter